Kyverna Therapeutics, Inc.
KYTX
$1.82
-$0.01-0.55%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 14.70% | 6.85% | |||
| Gross Profit | -14.70% | -6.85% | |||
| SG&A Expenses | 31.50% | 28.84% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.27% | 10.87% | |||
| Operating Income | -18.27% | -10.87% | |||
| Income Before Tax | -8.69% | -19.75% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -8.69% | -19.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.69% | -19.75% | |||
| EBIT | -18.27% | -10.87% | |||
| EBITDA | -18.41% | -10.88% | |||
| EPS Basic | -8.51% | -19.66% | |||
| Normalized Basic EPS | -22.66% | -13.78% | |||
| EPS Diluted | -8.51% | -19.66% | |||
| Normalized Diluted EPS | -22.66% | -13.78% | |||
| Average Basic Shares Outstanding | 0.18% | 0.07% | |||
| Average Diluted Shares Outstanding | 0.18% | 0.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||